MOUNTAIN VIEW, Calif.,
April 16, 2014 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its
fiscal quarter ended March 31, 2014
on Monday, May 5, 2014, following the
close of the U.S. financial markets. The Company will also
host an investor conference call and live webcast on the same day
at 5:00 p.m. Eastern Time /
2:00 p.m. Pacific Time to provide a
company update and discuss the financial results.
To access the webcast via the Internet, go to www.alexza.com,
under the "Investor Relations" link. Please log onto the
webcast prior to the start of the call to ensure time for any
software downloads that may be required to participate in the
webcast.
To access the live conference call, dial 888-680-0890 or
+1-617-213-4857 (international). The reference number to
enter the call is 42668133. Interested parties may also
pre-register for the call at
https://www.theconferencingservice.com/prereg/key.process?key=P6HCN8KHL
A replay of the conference call may be accessed at
www.alexza.com under the "Investor Relations" link, or by dialing
888-286-8010 or +1-617-801-6888 (international). The
reference number for the replay of the call is 24434341. A
replay of the call will be available for 14 days following the
event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE is Alexza's first commercial product. It has been
approved for sale by the U.S. Food and Drug Administration and the
European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for
ADASUVE in Europe, Latin America and the Commonwealth of
Independent States.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated news release
and conference call will contain forward-looking statements
that involve significant risks and uncertainties. Any
statement describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and its partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2013 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.